Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Erlocip 150 Tablet is to be taken empty stomach.
Erlocip 150 Tablet is an anti-cancer medication. Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that modulate their growth. This medicine works by binding the chemical messenger, EGFR, hence, inhibits the cancer signaling pathways mediated by EGFR. This is how it restricts further growth of the cancer cells.
It is not known whether it is safe to consume alcohol with Erlocip 150 Tablet. Please consult your doctor.
Erlocip 150 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Erlocip 150 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
It is not known whether Erlocip 150 Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Erlocip 150 Tablet is safe to use in patients with kidney disease. No dose adjustment of Erlocip 150 Tablet is recommended.
Use of this medicine is not advised in patients with severe kidney disease.
Erlocip 150 Tablet should be used with caution in patients with liver disease. Dose adjustment of Erlocip 150 Tablet may be needed. Please consult your doctor.
Limited information is available on the use of Erlocip 150 Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate liver disease.